<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05799742</url>
  </required_header>
  <id_info>
    <org_study_id>45535015.40000.0068</org_study_id>
    <nct_id>NCT05799742</nct_id>
  </id_info>
  <brief_title>Inguinal Hernia Repair and Male Fertility</brief_title>
  <official_title>Bilateral Inguinal Hernia Repair and Male Fertility: A Randomized Clinical Trial Comparing Lichtenstein Versus Laparoscopic Transabdominal Preperitoneal (TAPP) Technique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      General objective: To evaluate the fertility of adult men submitted to bilateral&#xD;
      herniorrhaphy with mesh placement by the Lichtenstein and laparoscopic approaches&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific objectives: To correlate pre and postoperative data (90 and 180 days) of adult men,&#xD;
      according to biochemistry parameters (hemogram and CRP), autoimmune (anti-sperm antibodies),&#xD;
      hormonal (FSH, LH and testosterone), perfusion and volume testicular (USG of testicles with&#xD;
      Doppler), spermogram, sexual changes, pain and quality of life (standard questionnaires).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2016</start_date>
  <completion_date type="Actual">December 15, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized clinical trial with two groups, in according to hernioplasty correction approach</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Masking couldn't be possible because of the surgical technique</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Sperm Volume</measure>
    <time_frame>Preoperative</time_frame>
    <description>Sperm Volume (in ml) measured by Semen analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sperm concentration</measure>
    <time_frame>Preoperative</time_frame>
    <description>Sperm concentration (million sperm/ml) measured by Semen analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sperm number</measure>
    <time_frame>Preoperative</time_frame>
    <description>Sperm number in million measured by Semen analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sperm motility</measure>
    <time_frame>Preoperative</time_frame>
    <description>Sperm motility in % of progression measured by Semen analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sperm morphology</measure>
    <time_frame>Preoperative</time_frame>
    <description>Sperm morphology, according to the Kruger classification, evaluated by Semen analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Testicular volume</measure>
    <time_frame>Preoperative</time_frame>
    <description>Testicular volume, in cm3, measured by testicular ultrasound</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Testicular vascularization</measure>
    <time_frame>Preoperative</time_frame>
    <description>Testicular vascularization, normal or not, measured by testicular Doppler ultrasound</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sperm Volume</measure>
    <time_frame>90th postoperative day</time_frame>
    <description>Sperm Volume (in ml) measured by Semen analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sperm concentration</measure>
    <time_frame>90th postoperative day</time_frame>
    <description>Sperm concentration (million sperm/ml) measured by Semen analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sperm number</measure>
    <time_frame>90th postoperative day</time_frame>
    <description>Sperm number in million measured by Semen analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sperm motility</measure>
    <time_frame>90th postoperative day</time_frame>
    <description>Sperm motility in % of progression measured by Semen analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sperm morphology</measure>
    <time_frame>90th postoperative day</time_frame>
    <description>Sperm morphology, according to the Kruger classification, evaluated by Semen analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Testicular volume</measure>
    <time_frame>90th postoperative day</time_frame>
    <description>Testicular volume, in cm3, measured by testicular ultrasound</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Testicular vascularization</measure>
    <time_frame>90th postoperative day</time_frame>
    <description>Testicular vascularization, normal or not, measured by testicular Doppler ultrasound</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sperm Volume</measure>
    <time_frame>180th postoperative day</time_frame>
    <description>Sperm Volume (in ml) measured by Semen analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sperm concentration</measure>
    <time_frame>180th postoperative day</time_frame>
    <description>Sperm concentration (million sperm/ml) measured by Semen analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sperm number</measure>
    <time_frame>180th postoperative day</time_frame>
    <description>Sperm number in million measured by Semen analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sperm motility</measure>
    <time_frame>180th postoperative day</time_frame>
    <description>Sperm motility in % of progression measured by Semen analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sperm morphology</measure>
    <time_frame>180th postoperative day</time_frame>
    <description>Sperm morphology, according to the Kruger classification, evaluated by Semen analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Semen analysis</measure>
    <time_frame>180th postoperative day</time_frame>
    <description>Volume (ml), Concentration (million/ml), Sperm number (million), Motility (% of progression), Morphology (Kruger classification)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Testicular volume</measure>
    <time_frame>180th postoperative day</time_frame>
    <description>Testicular volume, in cm3, measured by testicular ultrasound</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Testicular vascularization</measure>
    <time_frame>180th postoperative day</time_frame>
    <description>Testicular vascularization, normal or not, measured by testicular Doppler ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Follicle Stimulating Hormone (FSH) dosage</measure>
    <time_frame>Preoperative</time_frame>
    <description>Serum FSH (IU/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Luteinizing Hormone (LH) dosage</measure>
    <time_frame>Preoperative</time_frame>
    <description>Serum LH (IU/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Testosterone Hormone dosage</measure>
    <time_frame>Preoperative</time_frame>
    <description>Serum Testosterone (ng/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sex hormone-binding globulin (SHGB) dosage</measure>
    <time_frame>Preoperative</time_frame>
    <description>Serum SHGB (nmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual activity</measure>
    <time_frame>Preoperative</time_frame>
    <description>Satisfied or not with sexual performance, Changes in arousal, Changes in libido and Changes in ejaculation or orgasm (Specific questionnaires)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-of-life evaluation (SF-36 questionnaire)</measure>
    <time_frame>Preoperative</time_frame>
    <description>SF36 Domains: Role physical, Physical function, Role emotional, Energy, Emotional health, Social functioning, Bodily pain and General health. Scale ranging from 0 to 100, where zero is the worst state and 100 is the best.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>7th postoperative day</time_frame>
    <description>Visual Analog Scale (VAS) score ranging from 0 to 10, with 0 indicating no pain and 10 indicating the worst possible pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>30th postoperative day</time_frame>
    <description>Visual Analog Scale (VAS) score ranging from 0 to 10, with 0 indicating no pain and 10 indicating the worst possible pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follicle Stimulating Hormone (FSH) dosage</measure>
    <time_frame>90th postoperative day</time_frame>
    <description>Serum FSH (IU/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Luteinizing Hormone (LH) dosage</measure>
    <time_frame>90th postoperative day</time_frame>
    <description>Serum LH (IU/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Testosterone Hormone dosage</measure>
    <time_frame>90th postoperative day</time_frame>
    <description>Testosterone (ng/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sex hormone-binding globulin (SHGB) dosage</measure>
    <time_frame>90th postoperative day</time_frame>
    <description>Serum SHGB (nmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual activity</measure>
    <time_frame>90th postoperative day</time_frame>
    <description>Satisfied or not with sexual performance, Changes in arousal, Changes in libido and Changes in ejaculation or orgasm (Specific questionnaires)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-of-life evaluation (SF-36 questionnaire)</measure>
    <time_frame>90th postoperative day</time_frame>
    <description>SF36 Domains: Role physical, Physical function, Role emotional, Energy, Emotional health, Social functioning, Bodily pain and General health. Scale ranging from 0 to 100, where zero is the worst state and 100 is the best.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>90th postoperative day</time_frame>
    <description>Visual Analog Scale (VAS) score ranging from 0 to 10, with 0 indicating no pain and 10 indicating the worst possible pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follicle Stimulating Hormone (FSH) dosage</measure>
    <time_frame>180th postoperative day</time_frame>
    <description>Serum FSH (IU/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Luteinizing Hormone (LH) dosage</measure>
    <time_frame>180th postoperative day</time_frame>
    <description>Serum LH (IU/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Testosterone Hormone dosage</measure>
    <time_frame>180th postoperative day</time_frame>
    <description>Serum Testosterone (ng/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sex hormone-binding globulin (SHGB) dosage</measure>
    <time_frame>180th postoperative day</time_frame>
    <description>Serum SHGB (nmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual activity</measure>
    <time_frame>180th postoperative day</time_frame>
    <description>Satisfied or not with sexual performance, Changes in arousal, Changes in libido and Changes in ejaculation or orgasm (Specific questionnaires)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-of-life evaluation (SF-36 questionnaire)</measure>
    <time_frame>180th postoperative day</time_frame>
    <description>SF36 Domains: Role physical, Physical function, Role emotional, Energy, Emotional health, Social functioning, Bodily pain and General health. Scale ranging from 0 to 100, where zero is the worst state and 100 is the best.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>180th postoperative day</time_frame>
    <description>Visual Analog Scale (VAS) score ranging from 0 to 10, with 0 indicating no pain and 10 indicating the worst possible pain</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Inguinal Hernia Bilateral</condition>
  <arm_group>
    <arm_group_label>Lichtenstein</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional approach</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laparoscopy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental approach</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bilateral hernioplasty</intervention_name>
    <arm_group_label>Laparoscopy</arm_group_label>
    <arm_group_label>Lichtenstein</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  Age between 19 and 60 years old&#xD;
&#xD;
          -  Bilateral inguinal hernia&#xD;
&#xD;
          -  Primary and reducible inguinal hernia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 19 or more than 60 years old&#xD;
&#xD;
          -  ASA &gt;III&#xD;
&#xD;
          -  Genito-urinary infection&#xD;
&#xD;
          -  Immunodeficiency&#xD;
&#xD;
          -  History of testicular trauma2&#xD;
&#xD;
          -  History of surgery or pelvic radiotherapy&#xD;
&#xD;
          -  History of testicular disease&#xD;
&#xD;
          -  Fertility problems or sexual&#xD;
&#xD;
          -  Illness that can be infertile&#xD;
&#xD;
          -  Recurrent hernia&#xD;
&#xD;
          -  Unilateral hernia&#xD;
&#xD;
          -  Femoral or inguine-scrotal hernia&#xD;
&#xD;
          -  Imprisoned hernia&#xD;
&#xD;
          -  Use of Gonadotrophins&#xD;
&#xD;
          -  Use of anabolic steroids&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>February 17, 2023</study_first_submitted>
  <study_first_submitted_qc>April 3, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2023</study_first_posted>
  <last_update_submitted>April 3, 2023</last_update_submitted>
  <last_update_submitted_qc>April 3, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inguinal hernia</keyword>
  <keyword>Infertility</keyword>
  <keyword>Laparoscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Hernia, Inguinal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All individual participant data that underlie individual participant data that underlie collected during the trial, after deidentification (text, tables, figures, and appendices) will be shared. Study Protocol also will be available. Data will be available immediately following publication, no end dates, to anyone who wishes to access the data, for any types of analyses. Proposals should be directed to sergio.damous@hc.fm.usp.br</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be available immediately following publication, no end dates.</ipd_time_frame>
    <ipd_access_criteria>Proposals should be directed to sergio.damous@hc.fm.usp.br</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

